No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BHC240726C7500
- 0.24
- 0.000.00%
15min DelayClose Jul 22 13:16 ET
0.24High0.21Low
0.21Open0.24Pre Close35 Volume170 Open Interest7.50Strike Price825.00Turnover43.96%IV2.25%PremiumJul 26, 2024Expiry Date0.07Intrinsic Value100Multiplier4DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type0.5910Delta1.0665Gamma40.92Leverage Ratio-0.0178Theta0.0005Rho24.18Eff Leverage0.0032Vega
Intraday
- 5D
- Daily
News
Bausch Health Announces New CFO and Executive Compensation Plan
Bausch Health: Upon Charhon's Arrival, John Barresi, Company's Interim Chief Financial Officer, Will Resume His Role as SVP, Controller >BHC
Bausch Health: Upon Charhon's Arrival, John Barresi, Company's Interim Chief Financial Officer, Will Resume His Role as SVP, Controller >
Bausch Health: Jean-Jacques Charhon Will Join the Company as Chief Financial Officer on Aug. 19 >BHC
Bausch Health: Jean-Jacques Charhon Will Join the Company as Chief Financial Officer on Aug. 19 >
Bausch Health Welcomes Two New Members to the Executive Leadership Team
LAVAL, Quebec, July 19, 2024 – Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will
Analysts Are Optimistic We'll See A Profit From Bausch Health Companies Inc. (NYSE:BHC)
We feel now is a pretty good time to analyse Bausch Health Companies Inc.'s (NYSE:BHC) business as it appears the company may be on the cusp of a considerable accomplishment. Bausch Health
Raymond James Initiates Bausch Health(BHC.US) With Hold Rating, Announces Target Price $8
Raymond James analyst Michael W. Freeman initiates coverage on $Bausch Health(BHC.US)$ with a hold rating, and sets the target price at $8.According to TipRanks data, the analyst has a success rate
Comments
Bausch Health's revenue growth is unimpressive due to its lack of profitability. The share price crash may be an over-reaction, but improvements in business fundamentals are needed before considering a purchase. The company's long-term performance is concerning, and clear growth indicators are required for share price stability.
Strong Week for Bausch Health Companies (NYSE:BHC) Shareholders Doesn't Alleviate Pain of Three-year Loss 2
News Highlights
$Tesla(TSLA.US$ shares fell by 3.63%, closing at $164.90. Its options trading volume was 3.83 million. Call contracts account for 48.3% of the total trading volume. The most traded calls are contracts of $170 strike price that expire on Apr. 5th. The total volume reaches 106,470 with an open interest of 29,026. The most traded puts are contracts of a $165 strike p...
$Tesla(TSLA.US$ shares fell by 3.63%, closing at $164.90. Its options trading volume was 3.83 million. Call contracts account for 48.3% of the total trading volume. The most traded calls are contracts of $170 strike price that expire on Apr. 5th. The total volume reaches 106,470 with an open interest of 29,026. The most traded puts are contracts of a $165 strike p...
44
24
In today’s market, one of the biggest winners generating outsized interest is $Emergent BioSolutions(EBS.US$ . This mid-cap biotech company remains a unique turnaround story for investors, and many appear to be placing their bets on this company to come out of the pile as a key winner. Indeed, EBS stock has surged over 70% higher on some intriguing news this afternoon.
The company’s turnaround efforts appear to be receiving a jolt today, wit...
The company’s turnaround efforts appear to be receiving a jolt today, wit...
8
1
Read more